CliffBio
small molecule

REMODULIN

TREPROSTINIL

Loss of exclusivityMarch 2029latest FDA-listed patent expiry
CompanyUnited Laboratories →View the full company profile on CliffBio

Drug detail

Brand nameREMODULIN
Active ingredientTREPROSTINIL
Strength2.5MG/ML
Dosage formINJECTABLE
RouteINTRAVENOUS, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalMay 2002
Marketing statusRX

Listed patents

PatentExpiresType
7999007March 2029product
11723887December 2028substance
9593066December 2028substance
8658694September 2028use U-1437
8653137September 2028use U-1437

More from United Laboratories

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

REMODULIN patent cliff — loss of exclusivity March 2029 | CliffBio